First-line #sintilimab plus #platinum-etoposide is effective and safe in #ESSCLC, with multi-omics analyses revealing local and systemic #ImmuneLandscapes, enabling the construction of a non-invasive #biomarker model. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

A phase 3 #ClinicalTrial evaluating the efficacy of #socazolimab on #ESSCLC revealed that combining socazolimab with #carboplatin-#etoposide prolonged the overall survival without further side-effects. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

First-line #sintilimab plus #platinum-etoposide is effective and safe in #ESSCLC, with multi-omics analyses revealing local and systemic #ImmuneLandscapes, enabling the construction of a non-invasive #biomarker model. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

Induction with #etoposide and #carboplatin (EC), followed by #camrelizumab, apatinib and EC, and then maintenance with #camrelizumab and apatinib shows promising #antitumor activity in #ESSCLC. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

AstraZeneca receives positive recommendations for lung cancer treatments - PharmaTimes NICE endorses Imfinzi and Tagrisso for enhanced lung cancer care

#AstraZeneca #lungcancer #NICE #Imfinzi #durvalumab #Tagrisso #osimertinib #NICEpositiverecommendation #NICErecommendation #NHSEngland #NHSWales #ESSCLC #CASPIANPhaseIIItrial #overallsurvivalbenefits #ThoracicOncology #NSCLC #ADAURAphase3trial
pharmatimes.com/news/astraze...

Amgen’s lung cancer treatment gets conditional approval - PharmaTimes IMDYLLTRA offers new hope for patients with extensive-stage small cell lung cancer

#oncology #lungcancer @amgen.bsky.social #lungcancertreatment #IMDYLLTRA #tarlatamab #extensivestagesmallcelllungcancer #ESSCLC #ESSCLCpatients #UK #MHRA #conditionalmarketingauthorisation #Smallcelllungcancer #SCLC #DeLLphi301study #objectiveresponserate
pharmatimes.com/news/amgens-...